Alcon Inc./€ALC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alcon Inc.
Alcon Inc. is a global medical company specializing in eye care products. Headquartered in Geneva, Switzerland, Alcon operates in the healthcare industry with a focus on ophthalmology. The company offers a range of products including surgical equipment, contact lenses, and vision care products. Founded in 1945 as a small ophthalmic shop, it has grown to serve a diverse global market with operations across multiple countries. Alcon's strategic positioning leverages its extensive research and development capabilities, allowing it to innovate and adapt within the dynamic field of eye care.
- Ticker
- €ALC
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 25,000
- Headquarters
- Geneva, Switzerland
- Website
- www.alcon.com
Alcon Inc. Metrics
BasicAdvanced
€31B
52.78
€1.24
-
€0.31
0.47%
Price and volume
Market cap
€31B
52-week high
€74.04
52-week low
€52.32
Average daily volume
1M
Dividend rate
€0.31
Financial strength
Current ratio
2.496
Quick ratio
1.386
Long term debt to equity
0.239
Total debt to equity
0.246
Dividend payout ratio (TTM)
26.13%
Interest coverage (TTM)
4.34%
Profitability
EBITDA (TTM)
2,286.336
Gross margin (TTM)
58.11%
Net profit margin (TTM)
6.06%
Operating margin (TTM)
8.29%
Effective tax rate (TTM)
15.27%
Revenue per employee (TTM)
€397,150
Management effectiveness
Return on assets (TTM)
1.81%
Return on equity (TTM)
3.04%
Valuation
Price to earnings (TTM)
52.784
Price to revenue (TTM)
3.2
Price to book
1.32
Price to tangible book (TTM)
6.61
Price to free cash flow (TTM)
21.101
Free cash flow yield (TTM)
4.74%
Free cash flow per share (TTM)
3.094
Dividend yield (TTM)
0.47%
Forward dividend yield
0.47%
Growth
Revenue change (TTM)
7.84%
Earnings per share change (TTM)
-34.74%
3-year revenue growth (CAGR)
5.80%
3-year earnings per share growth (CAGR)
14.55%
3-year dividend per share growth (CAGR)
15.85%
Bulls say / Bears say
Alcon delivered 5% constant-currency sales growth in the third quarter, while core diluted EPS rose 15%. Growth across both Surgical and Vision Care suggests earnings momentum is not reliant on one business alone. (Business Wire)
New surgical equipment is gaining traction: equipment and other sales rose 19% in constant currency over the first nine months, led by launches including the UNITY platform and Valeda. If adoption continues, these launches can provide a growth driver beyond established products. (Business Wire)
The Neurotech acquisition adds ENCELTO, an FDA-approved treatment for MacTel, to Alcon’s retina portfolio. It gives the company a foothold in a new treatment area and may broaden its longer-term growth opportunities. (Business Wire)
Alcon tightened its 2026 outlook: it now expects about 6% sales growth and 12%–14% core EPS growth, with narrower margin guidance. The reduced upper end for EPS growth signals less room for the year to beat prior expectations. (Business Wire)
US competition is weighing on implantable lenses: third-quarter IOL sales fell 1% in constant currency, and the wider implantables segment declined 2%. Persistent pressure here could hold back Surgical growth despite strength in equipment and consumables. (Business Wire)
Alcon discontinued its PowerVision intraocular-lens programmes after clinical results showed unpredictable post-surgical outcomes for some patients. The decision led to a $402 million non-cash charge and highlights the risk that development spending may not produce viable products. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.